Milliez J M, Flouvat B, Delhotal B, Jannet D
Department of Obstetrics and Gynecology, Hopital Intercommunal, Creteil, France.
Obstet Gynecol. 1992 Aug;80(2):182-5.
We sought to determine whether subcutaneous administration of salbutamol resulted in plasma levels comparable to those achieved after intravenous or oral administration.
Twenty-nine women with preterm labor received subcutaneous infusion of salbutamol through a portable pump. We used three different rates of continuous infusion: a low rate of 3.33 micrograms/minute (20 subjects), an intermediate rate of 6.66 micrograms/minute (four subjects), and a high rate of 9.99 micrograms/minute (five subjects). Plasma salbutamol concentrations were assayed by high-performance liquid chromatography after 48 hours of continuous infusion in the subcutaneous tissue and after bolus injections (184 micrograms in the low-rate group and 368 micrograms in the intermediate- and high-rate groups).
Plasma salbutamol concentrations after 48 hours of subcutaneous infusion increased almost linearly with the rate of infusion: 6.29 +/- 1.58, 15.5 +/- 1.0, and 21.7 +/- 4.26 ng/mL in the low-, intermediate-, and high-rate groups, respectively (P less than .001 between the three groups). After bolus injection, maximum plasma concentrations were significantly different between the three groups (P less than .001) and from their respective baseline values (P less than .001): 8.33 +/- 1.9, 18.85 +/- 2.0, and 25.86 +/- 4.8 ng/mL in the low-, intermediate-, and high-rate groups, respectively.
Subcutaneous tocolysis can provide plasma salbutamol levels similar to the levels obtained orally or intravenously.
我们试图确定皮下注射沙丁胺醇后血浆水平是否与静脉注射或口服后达到的水平相当。
29名早产女性通过便携式泵接受皮下输注沙丁胺醇。我们使用了三种不同的持续输注速率：低速率3.33微克/分钟（20名受试者）、中速率6.66微克/分钟（4名受试者）和高速率9.99微克/分钟（5名受试者）。在皮下组织连续输注48小时后以及推注后（低速率组184微克，中速率组和高速率组368微克），通过高效液相色谱法测定血浆沙丁胺醇浓度。
皮下输注48小时后，血浆沙丁胺醇浓度几乎随输注速率呈线性增加：低速率组、中速率组和高速率组分别为6.29±1.58、15.5±1.0和21.7±4.26纳克/毫升（三组之间P<0.001）。推注后，三组之间的最大血浆浓度有显著差异（P<0.001），且与各自的基线值有显著差异（P<0.001）：低速率组、中速率组和高速率组分别为8.33±1.9、18.85±2.0和25.86±4.8纳克/毫升。
皮下抑制宫缩可提供与口服或静脉注射获得的水平相似的血浆沙丁胺醇水平。
